Life sciences company Neogen (NASDAQ:NEOG) will be reporting earnings tomorrow before market open. Here’s what to look for.
Neogen beat analysts’ revenue expectations by 1.4% last quarter, reporting revenues of $231.3 million, flat year on year. It was a strong quarter for the company, with a decent beat of analysts’ EPS estimates.
Is Neogen a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Neogen’s revenue to decline 2% year on year to $224.2 million, a reversal from the 4.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.12 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Neogen has missed Wall Street’s revenue estimates five times over the last two years.
With Neogen being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for healthcare equipment and supplies stocks. However, the whole sector has been hit hard over the last month as stocks in Neogen’s peer group are down 6.5% on average. Neogen is down 19.8% during the same time and is heading into earnings with an average analyst price target of $14 (compared to the current share price of $7.85).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
